Table 4.
Overall potential of plasma clotting kinetic parameters (mean ± SD) of the control group and patients with metabolic syndrome at baseline and after 1 and 2 months of A. melanocarpa extract therapy
| Parameter | Patients with metabolic syndrome | Control group | ||
|---|---|---|---|---|
| Baseline | 1 month | 2 months | ||
| TGt (s) | 140.7 ± 38.4 | 143.3 ± 48.89 | 183.2 ± 55.0++ | 151.0 ± 47.7 |
| F max (%T) | 70.8 ± 9.9 | 63.5 ± 14.28++ | 66.4 ± 14.1 | 63.2 ± 14.5 |
| Tf (s) | 59.5 ± 18.0** | 68.9 ± 44.42 | 68.7 ± 17.9 | 75.9 ± 26.4 |
| Fvo (%T/min) | 135.4 ± 48.5 | 121.9 ± 47.62 | 112.9 ± 32.8 | 113.6 ± 60.6 |
| C AUC (%T × min) | 1,182.4 ± 168.9* | 1,066.8 ± 246.14++ | 1,071.4 ± 233.5++ | 1,006.5 ± 290.4 |
TGt thrombin generation time, F max maximum clotting, Tf plasma clotting time, Fvo initial plasma clotting velocity, C AUC overall potential for clotting
* p = 0.05; ** p < 0.05 versus control group; ++ p < 0.05 versus baseline